Lilly Symbyax complete response
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly submits complete response during second quarter to an "approvable" letter for its olanzapine/fluoxetine combination Symbyax, the firm says July 24. Lilly "expects final FDA approval in 2004"; the NDA was submitted in fourth quarter 2002. The firm is highlighting the combo's rapid onset of action (1Pharmaceutical Approvals Monthly June 1, 2003, p. 5)...
You may also be interested in...
Lilly Highlights Symbyax Onset Of Action; Other Bipolar Presentations At APA
Lilly is highlighting a rapid onset of action and lack of treatment-emergent mania for its olanzapine/fluoxetine combination Symbyax, currently pending at FDA for the treatment of bipolar depression.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.